Real‐World Effectiveness and Safety of Fostamatinib in Difficult‐to‐Treat Immune Thrombocytopenia Patients. A Prospective, Multicenter Registry in France
American Journal of Hematology · 2026-04 · 101 (4) · 736-745
DOI: 10.1002/ajh.70194 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 08.01.2026. Verfasst von Guillaume Moulis und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Toulouse University Hospital, Toulouse, France. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Aminopyridines, Morpholines, Pyridines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Grifols.
Abstract (Originalsprache)
Fostamatinib is available in France since October 2021 for the treatment of adult chronic immune thrombocytopenia (ITP). French health authorities requested a 3‐year, prospective, multicenter registry to provide real‐world evidence about the effectiveness and safety of fostamatinib. Patients' characteristics, treatment response (ongoing exposure to fostamatinib and a platelet count ≥ 30 × 10 9 /L with no rescue in the previous 4 weeks) after 3, 6, 12, and 24 months (M); bleeding; fostamatinib discontinuation; adverse drug reactions (ADRs) and other events of interest have been analyzed. In total, 164 patients were included (median age: 59 years; 55.5% women; 84.1% had previous bleeding; 30 had secondary ITP; 89.0% had chronic ITP). The median ITP duration was 7.2 years and the median number of previous ITP treatments was 6. The response rate was 44.0% (70/159) at M3, 41.9% (62/148) at M6, 32.4% (44/136) at M12 and 20.0% (21/105) at M24. Concomitant treatment (mostly TPO‐RA) was used in > 60.0% of responders at each endpoint. The cumulative discontinuation rate at each endpoint was, respectively, 27.0%, 44.6%, 55.9%, and 76.2%. Seventy‐one (43.3%) patients experienced at least one bleeding during fostamatinib exposure; none was fatal. One hundred adverse drug reactions (8 serious) were observed in 61 (36.7%) patients, including diarrhea in 28 (17.1%) patients, arterial hypertension in 17 (10.4%). Seven thrombosis (4.3%) and 40 infections (12 serious) were reported in 25 patients (15.2%), mostly in patients with known risk factors. In conclusion, fostamatinib in combination with TPO‐RA should be considered in difficult‐to‐treat ITP patients. No new safety signal was observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Toulouse University Hospital, Toulouse, France.
- Clinical Investigation Center, Toulouse University Hospital, Toulouse, France.
- Department of Internal Medicine, National Referral Center for Autoimmune Cytopenias, Créteil University Hospital, Créteil, France.
- Department of Internal Medicine, Pessac University Hospital, University of Bordeaux, Bordeaux, France.
- Department of Hematology, Caen University Hospital, Caen, France.
- Department of Internal Medicine, Lille University Hospital, Lille, France.
ORCID-Profile: Clément Gourguechon, Thibault Comont, Maryse Lapeyre-Mestre
Förderung
- Grifols
Zitieren
APA
Moulis, G., Mahévas, M., Viallard, J. F., Chèze, S., Terriou, L., Audia, S., Moulinet, T., Ebbo, M., Gobert, D., Robbins, A., Gourguechon, C., Graveleau, J., Comont, T., Saunier, A., Faldlallah, J., Carreiro, M., Guilpain, P., Gil, H., Ruivard, M., …, & et le groupe des investigateurs de CARMEN‐France (2026). Real‐World Effectiveness and Safety of Fostamatinib in Difficult‐to‐Treat Immune Thrombocytopenia Patients. A Prospective, Multicenter Registry in France. American Journal of Hematology, 101(4), 736-745. https://doi.org/10.1002/ajh.70194
Vancouver
Moulis G, Mahévas M, Viallard JF, Chèze S, Terriou L, Audia S, et al. Real‐World Effectiveness and Safety of Fostamatinib in Difficult‐to‐Treat Immune Thrombocytopenia Patients. A Prospective, Multicenter Registry in France. American Journal of Hematology. 2026;101(4):736-745. doi:10.1002/ajh.70194
BibTeX
@article{Moulis2026,
author = {Moulis, Guillaume and Mahévas, Matthieu and Viallard, Jean-François and Chèze, Stéphane and Terriou, Louis and Audia, Sylvain and Moulinet, Thomas and Ebbo, Mikael and Gobert, Delphine and Robbins, Ailsa and Gourguechon, Clément and Graveleau, Julie and Comont, Thibault and Saunier, Aurélie and Faldlallah, Jehanne and Carreiro, Miguel and Guilpain, Philippe and Gil, Helder and Ruivard, Marc and Magy-Bertrand, Nadine and Dossier, Antoine and Leveneur, Yann and Delbrel, Xavier and Anthony, Bernard and Lifermann, François and Martin, Mikaël and Ledoux, Marie-Pierre and Roy-Péaud, Frédérique and Chabbert, Laurie and Lapeyre-Mestre, Maryse and Sommet, Agnès and Zadro, Yoann and Bonnotte, Bernard and Michel, Marc and Godeau, Bertrand and et le groupe des investigateurs de CARMEN‐France, et le groupe des investigateurs de CARMEN‐France},
title = {Real‐World Effectiveness and Safety of Fostamatinib in Difficult‐to‐Treat Immune Thrombocytopenia Patients. A Prospective, Multicenter Registry in France},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {4},
pages = {736--745},
doi = {10.1002/ajh.70194}
}
EUVIMED